Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 25/100

MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Tuesday, August 27, 2024 2 min read
Key Takeaway: MacroGenics, Inc. is facing a class action lawsuit related to alleged securities fraud due to misinformation about the safety data of its drug, vobramitamab duocarmazine. During a specific class period in 2024, it was revealed that the drug posed greater risks than previously communicated, leading to a drastic decline in the company's stock value. Shareholders are encouraged to participate in the lawsuit, with a deadline for lead plaintiff registration set for September 24, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • MGNX faced a class action lawsuit due to significant misrepresentations regarding the safety of its drug.
  • The stock declined by 77.4%, reflecting a substantial loss for investors.
  • The allegations involve misleading information that negatively impacted shareholder value.

Full Press Release Details

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).
Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=98138&from=3
CLASS PERIOD: March 7, 2024 to May 9, 2024
ALLEGATIONS: During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.
DEADLINE: September 24, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=98138&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MGNX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 24, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for MacroGenics shareholders?

The class period for MacroGenics shareholders is from March 7, 2024, to May 9, 2024.

What allegations were made against MacroGenics?

MacroGenics is accused of misrepresenting safety data regarding vobramitamab duocarmazine.

How much did MGNX's stock decline?

MGNX's stock declined 77.4%, translating to a drop of $11.36 per share.

What is the deadline to register for this class action?

The deadline to register for the class action is September 24, 2024.

Is there a cost to participate in the class action?

There is no cost or obligation to participate in this class action.

Tags: MGNX Viatris Investor Conferences Healthcare MacroGenics securities fraud class action lawsuit vobramitamab duocarmazine
Last updated: Aug 27, 2024